Q-omics provides the consensus-scored RPL34P34 profile across patient tissues and cancer cell-line models. RPL34P34 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RPL34P34 is differentially expressed in 9, with the highest sampling consensus in BLCA. Additionally, RPL34P34 RNA expression shows 8,109 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight BLCA, and LAML as cancer lineages where RPL34P34 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL34P34 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL34P34 survival associations across molecular data types. RPL34P34 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL34P34 RNA expression–survival associations across cancer types. High RPL34P34 expression shows unfavorable associations in LUAD and TGCT, but favorable associations in BLCA, SKCM, MESO and LGG. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify BLCA as the clearest survival context for RPL34P34 RNA expression.
This table summarizes RPL34P34 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL34P34. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL34P34 shows lower tumor expression in BLCA and higher tumor expression in COAD, LIHC, CHOL, KIRC and PAAD. The BLCA box plot shows higher RPL34P34 RNA expression in normal versus tumor tissue (log2 FC = −0.502, t-test p = .011).
This table shows molecular features associated with RPL34P34 in patient tissues and cancer cell lines. In patient samples, RPL34P34 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
